{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:01:14Z","timestamp":1785942074664,"version":"3.56.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Leshan Science and Technology Program","award":["No. 25ZDYFSF0061"],"award-info":[{"award-number":["No. 25ZDYFSF0061"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,17]]},"abstract":"<jats:p>\n                    This study aimed to evaluate the appropriateness of terlipressin use and assess its effects on coagulation parameters in 240 hospitalized patients treated between January 2024 and January 2025 in a real-world, single-center retrospective cohort. Clinical appropriateness, encompassing diagnostic indication, initial dosing, and administration route, was rigorously evaluated against current clinical guidelines and the manufacturer\u2019s prescribing information. Key coagulation parameters \u2013 prothrombin time, thrombin time, activated partial thromboplastin time, and fibrinogen \u2013 were analyzed before and after treatment using paired-sample\n                    <jats:italic toggle=\"yes\">t<\/jats:italic>\n                    tests, and patients were stratified into short-course (\u22645 days) and long-course (\u22656 days) therapy groups to examine the impact of treatment duration on outcomes using independent-sample\n                    <jats:italic toggle=\"yes\">t<\/jats:italic>\n                    tests. The analysis revealed a high degree of appropriateness: 231 patients (96.3%) received terlipressin for guideline-consistent indications, 143 patients (59.6%) were administered the recommended initial bolus dose of 2\u2009mg, and 185 cases (77.1%) employed the advised slow intravenous infusion route. Treatment with terlipressin significantly improved coagulation, with prothrombin time decreasing by a mean of 1.43 seconds and fibrinogen increasing by 0.11\u2009g\/L (both\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.01). However, extending the treatment course beyond 5 days offered no additional coagulation benefit, as no parameters showed significant improvement in the long-course compared with the short-course group (all\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05). These results underscore that terlipressin use was largely appropriate for indication and route, but extending therapy beyond 5 days provided no additional coagulation benefit. This finding supports stricter adherence to guideline-recommended treatment duration to promote more rational and effective use of terlipressin in clinical practice.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000048254","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:02:15Z","timestamp":1776434535000},"page":"e48254","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Appropriateness of terlipressin use and its association with clinical efficacy and safety: A real-world cohort study of 240 hospitalized patients"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3187-1531","authenticated-orcid":false,"given":"Yifei","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Leshan Hospital of Traditional Chinese Medicine, Affiliated to Chengdu University of Chinese Medicine, Leshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Leshan Hospital of Traditional Chinese Medicine, Affiliated to Chengdu University of Chinese Medicine, Leshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Leshan Hospital of Traditional Chinese Medicine, Affiliated to Chengdu University of Chinese Medicine, Leshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Leshan Hospital of Traditional Chinese Medicine, Affiliated to Chengdu University of Chinese Medicine, Leshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Leshan Hospital of Traditional Chinese Medicine, Affiliated to Chengdu University of Chinese Medicine, Leshan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260605","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.gastro.2020.08.054","article-title":"Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics: relationship with acute-on-chronic liver failure and prognosis.","volume":"160","author":"Sol\u00e9","year":"2021","journal-title":"Gastroenterology"},{"key":"R2-20260605","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.3390\/cancers16112042","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma and their hepatic-related side effects: a review.","volume":"16","author":"Ruli","year":"2024","journal-title":"Cancers"},{"key":"R3-20260605","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/jcm12010260","article-title":"Management of hemorrhagic shock: physiology approach, timing and strategies.","volume":"12","author":"Bonanno","year":"2022","journal-title":"J Clin Med"},{"key":"R4-20260605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12876-025-04094-5","article-title":"Portal vein thrombosis and esophageal-gastric variceal bleeding in cirrhosis: shared risk factors and causal relationship.","volume":"25","author":"Lin","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"R5-20260605","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases.","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"key":"R6-20260605","doi-asserted-by":"crossref","first-page":"340","DOI":"10.21037\/atm.2020.02.135","article-title":"Effect of terlipressin on renal function in cirrhotic patients with acute upper gastrointestinal bleeding.","volume":"8","author":"Zhang","year":"2020","journal-title":"Ann Transl Med"},{"key":"R7-20260605","first-page":"1","article-title":"The application of terlipressin in the management of ascites in liver cirrhosis: current status and prospects.","volume":"85","author":"Shen","year":"2024","journal-title":"Br J Hosp Med (Lond)"},{"key":"R8-20260605","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1080\/14656566.2023.2244427","article-title":"Terlipressin in the management of liver disease.","volume":"24","author":"Scheinberg","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"R9-20260605","first-page":"775","article-title":"Effect of terlipressin on renal function in cirrhotic patients with esophageal gastric varices bleeding and normal baseline renal function.","volume":"27","author":"Lin","year":"2022","journal-title":"Chin J Clin Pharmacol Ther"},{"key":"R11-20260605","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jhep.2022.06.001","article-title":"EASL clinical practice guidelines on the management of hepatic encephalopathy.","volume":"77","author":"Montagnese","year":"2022","journal-title":"J Hepatol"},{"key":"R12-20260605","doi-asserted-by":"crossref","first-page":"17562848221098253","DOI":"10.1177\/17562848221098253","article-title":"Practice guidance for the use of terlipressin for liver cirrhosis\u2013related complications.","volume":"15","author":"Qi","year":"2022","journal-title":"Ther Adv Gastroenterol"},{"key":"R13-20260605","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1111\/liv.14703","article-title":"Terlipressin has stood the test of time: clinical overview in 2020 and future perspectives.","volume":"40","author":"Kulkarni","year":"2020","journal-title":"Liver Int"},{"key":"R14-20260605","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1007\/s00216-025-05944-7","article-title":"Understanding the chemical stability of peptidomimetic therapeutics using high-resolution mass spectrometry: a study of terlipressin and its degradation products.","volume":"417","author":"Chawathe","year":"2025","journal-title":"Anal Bioanal Chem"},{"key":"R15-20260605","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/gastroent14040031","article-title":"Terlipressin for the prevention and treatment of renal decline in hepatorenal syndrome: a drug profile.","volume":"14","author":"Ayyad","year":"2023","journal-title":"Gastroenterol Insights"},{"key":"R16-20260605","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2147\/RMHP.S442692","article-title":"The rate of infusion represents an important aspect of administering anticancer agents.","volume":"16","author":"Lan","year":"2023","journal-title":"Risk Manag Healthc Policy"},{"key":"R17-20260605","doi-asserted-by":"crossref","first-page":"68","DOI":"10.14712\/23362936.2016.7","article-title":"Terlipressin induced severe hyponatremia.","volume":"117","author":"\u0160\u00edma","year":"2016","journal-title":"Prague Med Rep"},{"key":"R18-20260605","first-page":"180","article-title":"Extensive epidermal necrosis due to terlipressin.","volume":"13","author":"Yefet","year":"2011","journal-title":"Israel Med Assoc J"},{"key":"R19-20260605","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1080\/14656566.2024.2409941","article-title":"The pharmacological management of alcohol-related cirrhosis: what\u2019s new?","volume":"25","author":"Verma","year":"2024","journal-title":"Expert Opin Pharmacother"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:23:46Z","timestamp":1785939826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":18,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048254","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"2025-11-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}